HPA046356

antibody from Atlas Antibodies

Targeting: C4A C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG

Provider product page for HPA046356

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [2]
Comments [0]
Validations [0]

Submit

Product number: HPA046356 - Provider product page
Provider: Atlas Antibodies
Proper citation: Atlas Antibodies Cat#HPA046356, RRID:AB_2679635
Product name: Anti-C4A
Antibody type: Polyclonal
Description: Polyclonal Antibody against Human C4A, Gene description: complement component 4A (Rodgers blood group), Alternative Gene Names: C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG, Validated applications: IHC, Uniprot ID: P0C0L4, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Reactivity: Human
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 100 µl
Concentration: 0.05 mg/ml
Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Handling: The antibody solution should be gently mixed before use.

C4A protein structure - HPA046356 shown in red.

Submitted references A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study

Bergström S, Öijerstedt L, Remnestål J, Olofsson J, Ullgren A, Seelaar H, van Swieten J, Synofzik M, Sanchez-Valle R, Moreno F, Finger E, Masellis M, Tartaglia C, Vandenberghe R, Laforce R, Galimberti D, Borroni B, Butler C, Gerhard A, Ducharme S, Rohrer J, Månberg A, Graff C, Nilsson P, Jiskoot L, Rowe J, de Mendonça A, Tagliavini F, Santana I, Le Ber I, Levin J, Danek A, Otto M, Frisoni G, Ghidoni R, Sorbi S, Pasquier F, Jelic V, Andersson C, Afonso S, Almeida M, Anderl-Straub S, Antonell A, Archetti S, Arighi A, Balasa M, Barandiaran M, Bargalló N, Bartha R, Bender B, Benussi A, Benussi L, Bessi V, Binetti G, Black S, Bocchetta M, Borrego-Ecija S, Bras J, Bruffaerts R, Cañada M, Cantoni V, Caroppo P, Cash D, Castelo-Branco M, Convery R, Cope T, Di Fede G, Díez A, Duro D, Fenoglio C, Ferrari C, Ferreira C, Fox N, Freedman M, Fumagalli G, Gabilondo A, Gasparotti R, Gauthier S, Gazzina S, Giaccone G, Gorostidi A, Greaves C, Guerreiro R, Heller C, Hoegen T, Indakoetxea B, Jiskoot L, Karnath H, Keren R, Langheinrich T, Leitão M, Lladó A, Lombardi G, Loosli S, Maruta C, Mead S, Meeter L, Miltenberger G, van Minkelen R, Mitchell S, Moore K, Nacmias B, Nicholas J, Olives J, Ourselin S, Padovani A, Panman J, Papma J, Peakman G, Pievani M, Pijnenburg Y, Polito C, Premi E, Prioni S, Prix C, Rademakers R, Redaelli V, Rittman T, Rogaeva E, Rosa-Neto P, Rossi G, Rosser M, Santiago B, Scarpini E, Schönecker S, Semler E, Shafei R, Shoesmith C, Tábuas-Pereira M, Tainta M, Taipa R, Tang-Wai D, Thomas D, Thompson P, Thonberg H, Timberlake C, Tiraboschi P, Todd E, Van Damme P, Vandenbulcke M, Veldsman M, Verdelho A, Villanua J, Warren J, Wilke C, Woollacott I, Wlasich E, Zetterberg H, Zulaica M
Molecular Neurodegeneration 2021;16(1)

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy

Signorelli M, Ayoglu B, Johansson C, Lochmüller H, Straub V, Muntoni F, Niks E, Tsonaka R, Persson A, Aartsma‐Rus A, Nilsson P, Al‐Khalili Szigyarto C, Spitali P
Journal of Cachexia, Sarcopenia and Muscle 2019;11(2):505-517